| Document |
Document Title |
|
WO/2002/070468A2 |
Compounds which can be represented by the general formula (I) and in which A is selected independently from the carboxamide group, the thiocarboxamide group, and the carbonyl group, -R¿1? is selected from an alkyl group having from 1 to...
|
|
WO/2002/068381A2 |
Compounds, compositions and methods treating arthritic disorders such as osteoarthritis or rheumatoid arthritis, and for treating other diseases associated with altered mitochondrial function, such as cancer, psoriasis, stroke, Alzheimer...
|
|
WO/2002/068377A1 |
(R) -2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treat...
|
|
WO/2002/066421A1 |
Molecules of the general formula (I) without intramolecular peptidic bonds, able to mimic the RGD peptide, containing ARG-GLY-ASP motif 'arginine-glycine-aspartic acid' (that is a potent inhibitor, in vivo and in vitro, of cellular adhes...
|
|
WO/2002/064136A2 |
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases m...
|
|
WO/2002/062762A2 |
Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO/2002/058690A2 |
The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration ...
|
|
WO/2002/053090A2 |
The invention concerns a medicinal combination, for treating diabetes, in particular type 2 diabetes, associating a biguanine, in particular a N-dimethylbiguanine, as first medicine, and a carrier agent for said biguanine, as second medi...
|
|
WO/2002/052957A1 |
The invention relates to addition and/or co-ordination compounds consisting of creatine and citric acid in the ratio of >1.0 to 3.0: 1.0. Said compounds are characterised in that they have (KBr) bands in the IR spectrum, where $g(n)= 342...
|
|
WO/2002/036554A2 |
Novel amidino-urea 5-HT¿7? receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treati...
|
|
WO/2002/032392A1 |
Skin pore minimizers containing as the active ingredient compounds of the following general formula: R?1¿-OG or salts thereof [wherein R?1¿ is C¿8-32? alkyl or alkenyl; and OG is a residue derived from a polyhydric alcohol, a monosacc...
|
|
WO/2002/030877A1 |
The invention relates to chemistry, in particular to the production of disinfectants which are based on polyalkylene guanidines and polyoxialkylene guanidines and can be used as environmentally safe and efficient disinfectants for medici...
|
|
WO/2002/028825A2 |
Phenyl acetamide compounds are described, including compounds of Formula (I): or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R?3¿-R?6¿, R?11¿, B, Y and W are set forth in the specification. The compounds of...
|
|
WO2000063193A9 |
This invention relates to novel polymorphic/pseudopolymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having formula (I). The invention also relates to a pharmaceutical composition compr...
|
|
WO/2002/022626A1 |
Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologica...
|
|
WO/2002/022553A2 |
This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides.
|
|
WO/2002/022135A1 |
The present invention describes a method for providing creatine to an animal which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.
|
|
WO/2002/020475A2 |
The present invention provides compounds which inhibit serine protease activity of matriptase or MTSP1. Also provided are pharmaceutical compositions comprising those compounds and methods of using the compounds and pharmceutical composi...
|
|
WO/2002/018327A2 |
Compounds of formula (IA) and (IB) are new where the variables R?1¿ through R?10¿ have the values set forth herein. Such compounds have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutica...
|
|
WO/2002/016318A1 |
The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pa...
|
|
WO/2002/014329A1 |
Compositions for the inhibition of the formation of new vaculature by angiogenesis are provided as in compounds which are salts comprising as an acidic component a compound of formula (1) wherein: R?1¿, R?2¿ and R?3¿ are each independ...
|
|
WO/2002/012166A2 |
The invention provides triamine derivative melanocortin receptor ligands of the formula (1), wherein R?1¿ to R?8¿ and n have the meanings provided herein. The invention further provides methods of using the ligands to alter or regulate...
|
|
WO/2002/012177A1 |
This invention relates to compositions comprising metformin and succinic acid or a pharmaceutically acceptable salt thereof. More specifically, this invention relates to compositions comprising metformin and succinic acid or a pharmaceut...
|
|
WO/2002/012168A1 |
A compound having general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
|
|
WO/2002/008175A2 |
Arginine saccharate and its use in the prevention and treatment of cardiovascular and circulatory disorders such as atherosclerosis and hypertension. The compound is synthesized by mixing arginine with a salt of saccharic acid. Pharmaceu...
|
|
WO/2002/004406A2 |
The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocyline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2002/000614A1 |
The present invention relates to compounds of the formula (I) wherein X is selected from O, S, SO, SO¿2?, NR, CR¿2?, C(OH)R and C=O; each R?1¿ is independently selected from H, C¿1-12?alkyl and C¿3-12?aryl; R?2¿ is selected from H,...
|
|
WO/2001/098235A2 |
The invention relates to 3,4-dihydroxybenzyl-substituted carbonic acid derivatives, to their production, and to their use as antioxidants or free-radical scavengers, especially in cosmetic and pharmaceutical preparations and in foodstuff...
|
|
WO/2001/096281A1 |
Double fumarates of L-carnitine or isovaleryl L-carnitine and an amino acid are disclosed which are useful as active ingredients of food supplements, dietary supplements or drugs.
|
|
WO/2001/094292A1 |
The invention concerns the preparation of cationic surfactants derived from the condensation of an acid, preferably a fatty acid or a hydroxy acid with a number of carbon atoms of 8 - 14 with esterified amino acids, preferably basic-type...
|
|
WO/2001/092207A1 |
A process of reacting a compound having an NH group with a thiocyanate, a cyanamide, a nitrile, or an ester in the presence of a silylating agent to thereby obtain the corresponding nitrogen-containing addition or substitution product. T...
|
|
WO/2001/092210A1 |
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of th...
|
|
WO/2001/092218A2 |
Novel 'bispolyamine' inhibitor compounds of polyamine transport are disclosed. These compounds are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins,...
|
|
WO/2001/087840A1 |
Novel propanoic acid derivatives are integrin receptor antagonists or inhibitors, in particular of the avb3 integrin receptor. The compounds of the invention are for instance useful for the treatment of solid tumors by inhibition of angi...
|
|
WO/2001/087829A1 |
The invention relates to bisacylguanidine of formula (I), wherein one of radicals is R?1¿, R?2¿, R?3¿, R?4¿, or R?5¿ and one of the radicals is R?6¿, R?7¿, R?8¿, R?9¿ or R?10¿, and to its physiologically acceptable salts and/or...
|
|
WO/2001/085728A2 |
The present invention relates to optically pure 8-(substituted piperidino)-benzo [i,j] quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and t...
|
|
WO/2001/086057A1 |
The invention relates to an agent for coloring fibers, which is prepared before use by mixing an acidic component (A1), which contains at least one enamine of formula (I)/(Ia), with a component (A2), which contains a Schiff's base of for...
|
|
WO/2001/085676A1 |
The invention relates to biocidal polymers with a guanidine salt base, characterised in that they are representatives of the series of polyoxyalkylene guanidines and their salts and in that they represent a product of the polycondensatio...
|
|
WO/2001/085677A1 |
The invention concerns novel amino acid derivatives and their use as medicines. Said derivatives have an inhibiting activity towards NO-synthase enzymes producing nitrogen monoxide NO and/or (optionally): either an activity trapping reac...
|
|
WO/2001/083429A1 |
Compounds represented by the formular (A), tautomers thereof, or medicinally acceptable salts of both exhibit an NOS-inhibitory activity and are useful as drugs in the treatment of various diseases.
|
|
WO/2001/079359A2 |
Anti-fouling agents comprising isothiouronium salts, guanidinium salts, and their conjugate base analogs are provided. Anti-fouling coating compositions that include these anti-fouling agents are also provided. Such anti-fouling agents a...
|
|
WO/2001/072701A1 |
A ceramide derivative of the formula (I).
|
|
WO/2001/070204A2 |
The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.
|
|
WO/2001/062735A1 |
The present invention relates to new compounds for the inhibition of blood clotting proteins, and more particularly, to malonic acid derivatives of the formula (I), wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicat...
|
|
WO/2001/062242A1 |
A compound represented by the formulae (A) or (B) wherein R¿1? is H, R¿5?, (a), (b), (c), (d), (e), (f), (g), — (CH¿2?)¿n?OC(O)R¿5?, —(CH¿2?)¿n?OR¿5?, or —(CH¿2?)¿n?-N-R¿6?; each R¿2? and R¿3? individually is H, (CH¿2...
|
|
WO/2001/058860A1 |
The invention concerns novel arginine-derived surface active compounds consisting of monoacyl glycerides and diacyl glycerides of general formula (I) and designed to act as surface active agents with antimicrobial activity. The activity ...
|
|
WO/2001/058859A1 |
The invention generally relates to a novel kind of arginine mimetics which are inhibitors of the factor X¿a?. The invention also relates to pharmaceutical compositions that contain said mimetics and to the use of said arginine mimetics ...
|
|
WO/2001/056975A1 |
The invention concerns novel substituted imide derivatives of general formula (I), wherein R?1¿ represents optionally substituted cycloalkyl; R?2¿ represents optionally substituted alkyl or optionally substituted cycloalkyl; R?3¿ repr...
|
|
WO/2001/055107A2 |
The present invention relates to novel aromatic amines and amides of general formula (I) and to the use of these amines and amides for the treatment of obesity, anorexia, inflammation, mental disorders and other diseases associated with ...
|
|
WO/2001/055098A1 |
The present invention is directed to a compound having the structure (I): and acceptable salts, polypeptides, and pro-forms thereof, wherein R is selected from the group consisting of: (a) substituted glycerols; wherein n is an integer f...
|
